secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2021-08-04T23:59:59+00:00
Accession:  0001104659-21-100078
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Q2 net loss $30.8M; rusfertide gets FDA Breakthrough Therapy; Phase 3 on track
--------------------------------------------------------------------------------

- Net loss $30.8M ($0.69/share) vs $19.4M ($0.59) in Q2 2020; cash $380.4M expected to fund through 2024.
- Rusfertide granted FDA Breakthrough Therapy for polycythemia vera; Phase 3 start expected early 2022.
- Janssen collaboration amended: Janssen leads worldwide development; Protagonist eligible for ~$900M milestones plus $80M received.
- Completed public offering of 3.5M shares at $37.75, raising ~$132.2M gross proceeds.
- PN-943 Phase 2 data for ulcerative colitis anticipated in Q2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465921100078/0001104659-21-100078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465921100078/tm2124049d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-100078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer